Research

Items by Shur, Jagdeep

Up a level
Export as [feed] RSS 1.0 [feed] Atom [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
Number of items: 27.

2015

Shur, J., Saluja, B., Lee, S., Tibbatts, J. and Price, R., 2015. Effect of device design and formulation on the in vitro comparability for multi-unit dose dry powder inhalers. AAPS Journal, 17 (5), pp. 1105-1116.

2014

Depasquale, R., Lee, S. L., Saluja, B., Shur, J. and Price, R., 2014. The influence of secondary processing on the structural relaxation dynamics of fluticasone propionate. AAPS PharmSciTech, 16 (3), pp. 589-600. Item availability may be restricted.

2013

2012

Shur, J., Lee, S., Adams, W., Lionberger, R., Tibbatts, J. and Price, R., 2012. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers. AAPS Journal, 14 (4), pp. 667-676.

2011

Shur, J. and Price, R., 2011. The influence of crystals, particles and powders on the performance of dry powder inhalers. In: 2011 AIChE Annual Meeting, Conference Proceedings. AIChE.

2010

Kinnunen, H., Shur, J., Hebbink, G., Muresan, A. S. and Price, R., 2010. Lactose fluidisation properties and their relationship to dry powder inhaler performance. Journal of Pharmacy and Pharmacology, 62 (10), pp. 1342-1343.

Pitchayajittipong, C., Price, R., Shur, J., Kaerger, J. S. and Edge, S., 2010. Characterisation and functionality of inhalation anhydrous lactose. International Journal of Pharmaceutics, 390 (2), pp. 134-141.

2009

Begat, P., Morton, D. A. V., Shur, J., Kippax, P., Staniforth, J. N. and Price, R., 2009. The role of force control agents in high-dose dry powder inhaler formulations. Journal of Pharmaceutical Sciences, 98 (8), pp. 2770-2783.

2008

Shur, J., Nevell, T. G., Ewen, R. J., Price, R., Smith, A., Barbu, E., Conway, J. H., Carroll, M. P., Shute, J. K. and Smith, J. R., 2008. Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy. Journal of Pharmaceutical Sciences, 97 (11), pp. 4857-68.

Edge, S., Mueller, S., Price, R. and Shur, J., 2008. Factors affecting defining the quality and functionality of excipients used in the manufacture of dry powder inhaler products. Drug Development and Industrial Pharmacy, 34 (9), pp. 966-73.

Jones, M., Harris, H., Hooton, J. C., Shur, J., King, G. S., Mathoulin, C. A., Nichol, K., Smith, T. L., Dawson, M. L., Ferrie, A. R. and Price, R., 2008. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. European Journal of Pharmaceutics and Biopharmaceutics, 69 (2), pp. 496-507.

Shur, J., Nevell, T. G., Shute, J. K. and Smith, J. R., 2008. The spray drying of unfractionated heparin:optimization of the operating parameters. Drug Development and Industrial Pharmacy, 34 (6), pp. 559-68.

Jones, M., Young, P. M., Traini, D., Shur, J., Edge, S. and Price, R., 2008. The use of atomic force microscopy to study the conditioning of micronised budesonide. International Journal of Pharmaceutics, 357 (1-2), pp. 314-317.

2007

Broughton-Head, V. J., Shur, J., Carroll, M. P., Smith, J. R. and Shute, J. K., 2007. Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology, 293 (5), L1240-9.

Broughton-Head, V. J., Smith, J. R., Shur, J. and Shute, J. K., 2007. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulmonary pharmacology & therapeutics, 20 (6), pp. 708-17.

2006

Pitchayajittipong, C., Shur, J. and Price, R., 2006. The generation of spherical crystalline particles via a novel particle engineering process. Journal of Pharmacy and Pharmacology, 58, A76-A77.

This list was generated on Mon Aug 31 14:16:55 2015 IST.